{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:13:18Z","timestamp":1793945598528,"version":"4.8.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib (ibr) revolutionized chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) treatment, although treatment-related toxicities limit the use of some BTK inhibitors. Zanubrutinib, a potent next-generation BTK inhibitor, has higher selectivity than ibrutinib or acalabrutinib. The ongoing phase 2, single-arm BGB-3111-215 study investigates the safety and efficacy of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and\/or acalabrutinib. Here, results in patients with CLL\/SLL are presented. Patients received zanubrutinib 160 mg twice daily or 320 mg once a day. With a 34.5-month median follow-up, 71 patients (ibrutinib intolerant only, n = 44; acalabrutinib intolerant only, n = 17; ibrutinib and acalabrutinib intolerant, n = 10) received \u22651 zanubrutinib dose. On zanubrutinib, 54% (28\/52) of ibrutinib-intolerant patients and 70% (19\/27) of acalabrutinib-intolerant patients experienced no recurrence of intolerance adverse events (AEs); 60% and 72% of intolerance AEs did not recur, respectively. Of recurrent ibrutinib-intolerance AEs, 64% were lower grade; 44% of acalabrutinib-intolerance AEs were lower grade. No intolerance AEs recurred at a higher grade with zanubrutinib. The most common recurrent ibrutinib-intolerance and acalabrutinib-intolerance AEs were fatigue and diarrhea, respectively. The most common treatment-emergent AEs (TEAEs) with zanubrutinib were fatigue (32%) and COVID-19 (28%). Grade \u22653 TEAEs occurred in 61%, serious TEAEs in 32%, and TEAEs leading to discontinuation in 11%. Of 67 efficacy-evaluable patients, 94% experienced disease control: 30% had a best response of stable disease and 64% had a partial or complete response. These data demonstrate that patients intolerant of ibrutinib\/acalabrutinib may benefit from switching to zanubrutinib therapy. This trial was registered at www.ClinicalTrials.gov as #NCT04116437.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015493","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T14:33:18Z","timestamp":1746628398000},"page":"4100-4110","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Zanubrutinib is well tolerated and effective in patients with CLL\/SLL intolerant of ibrutinib\/acalabrutinib: updated results"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"first","affiliation":[{"name":"1Division of Medical Oncology, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5144-6710","authenticated-orcid":false,"given":"John M.","family":"Burke","sequence":"additional","affiliation":[{"name":"2Rocky Mountain Cancer Centers, US Oncology Research, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Cultrera","sequence":"additional","affiliation":[{"name":"3Florida Cancer Specialists & Research Institute, Fort Myers, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habte A.","family":"Yimer","sequence":"additional","affiliation":[{"name":"4Texas Oncology-Tyler, US Oncology Research, Tyler, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed F.","family":"Zafar","sequence":"additional","affiliation":[{"name":"3Florida Cancer Specialists & Research Institute, Fort Myers, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Misleh","sequence":"additional","affiliation":[{"name":"5Medical Oncology Hematology Consultants, Newark, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramanya S.","family":"Rao","sequence":"additional","affiliation":[{"name":"6Affiliated Oncologists, Alpha Med Physicians Group, Tinley Park, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Farber","sequence":"additional","affiliation":[{"name":"7Atlantic Hematology Oncology, Morristown Medical Center, Morristown, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Cohen","sequence":"additional","affiliation":[{"name":"8BeOne Medicines Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yao","sequence":"additional","affiliation":[{"name":"9BeOne Medicines Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Idoine","sequence":"additional","affiliation":[{"name":"8BeOne Medicines Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"An","sequence":"additional","affiliation":[{"name":"8BeOne Medicines Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6724-290X","authenticated-orcid":false,"given":"Ian W.","family":"Flinn","sequence":"additional","affiliation":[{"name":"10Tennessee Oncology and OneOncology, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff P.","family":"Sharman","sequence":"additional","affiliation":[{"name":"11Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"issue":"3","key":"2025082609465429500_bib1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.6004\/jnccn.2015.0045","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 1.2015","volume":"13","author":"Zelenetz","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"2025082609465429500_bib2","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: a review","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"issue":"12","key":"2025082609465429500_bib3","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"},{"key":"2025082609465429500_bib4","volume-title":"Imbruvica (ibrutinib). Package insert","year":"2019"},{"key":"2025082609465429500_bib5","volume-title":"Calquence (acalabrutinib). Package insert","year":"2019"},{"issue":"1","key":"2025082609465429500_bib6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jha2.638","article-title":"A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States","volume":"4","author":"Mato","year":"2023","journal-title":"EJHaem"},{"issue":"5","key":"2025082609465429500_bib7","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"35","key":"2025082609465429500_bib8","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.2217\/fon-2021-0964","article-title":"Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia","volume":"17","author":"Hou","year":"2021","journal-title":"Future Oncol"},{"issue":"7","key":"2025082609465429500_bib9","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1080\/10428194.2021.1876863","article-title":"Outcomes in chronic lymphocytic leukemia patients on novel agents in the US Veterans Health Administration System","volume":"62","author":"Frei","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"31","key":"2025082609465429500_bib10","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"17","key":"2025082609465429500_bib11","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J Med Chem"},{"key":"2025082609465429500_bib12","volume-title":"Brukinsa (zanubrutinib). Package insert","year":"2021"},{"key":"2025082609465429500_bib13","volume-title":"Brukinsa (zanubrutinib). Summary of product characteristics","year":"2021"},{"key":"2025082609465429500_bib14","unstructured":"BeiGene\n          . BeiGene receives new approvals for BRUKINSA (zanubrutinib) in China. Accessed 25 May 2023. https:\/\/ir.beigene.com\/news\/beigene-receives-new-approvals-for-brukinsa-zanubrutinib-in-china\/7e5cd979-7835-4263-8dde-f426c721fb3e\/."},{"issue":"1","key":"2025082609465429500_bib15","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","article-title":"Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study","volume":"10","author":"Shadman","year":"2023","journal-title":"Lancet Haematol"},{"issue":"4","key":"2025082609465429500_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"2025082609465429500_bib17","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"23","key":"2025082609465429500_bib18","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1200\/JCO.2012.43.3748","article-title":"Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia","volume":"30","author":"Cheson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"27","key":"2025082609465429500_bib19","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"19","key":"2025082609465429500_bib20","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2025082609465429500_bib21","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"2025082609465429500_bib22","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"2025082609465429500_bib23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"2025082609465429500_bib24","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.clml.2018.06.016","article-title":"Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma or mantle cell lymphoma","volume":"18","author":"O'Brien","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2025082609465429500_bib25","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1038\/s41375-021-01252-y","article-title":"Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies","volume":"35","author":"Furman","year":"2021","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/16\/4100\/2406480\/blooda_adv-2024-015493-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/16\/4100\/2406480\/blooda_adv-2024-015493-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T13:47:01Z","timestamp":1756216021000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/16\/4100\/537143\/Zanubrutinib-is-well-tolerated-and-effective-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":25,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,8,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015493","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,26]]},"published":{"date-parts":[[2025,8,13]]}}}